Biocomposites introduced SYNICEM hip, knee and shoulder preformed spacers in the United Kingdom.
SYNICEM spacers are antibiotic-loaded, preformed spacers designed to overcome the challenges of traditional intra-operative molded and handmade spacers. They help support revisions of the hip, knee and shoulder by preserving articular space and aiding the treatment of infection. Precision-engineered for consistency and structural uniformity, SYNICEM spacers provide a high local concentration of gentamicin and provide case-by-case flexibility to save surgeons time during their procedures.
The launch of SYNICEM spacers in the UK follows Biocomposites’ acquisition of French-based medical device manufacturer, Synimed, in 2022. Synimed specializes in bone cement and polymer-related products using in-house proprietary core polymer production and formulation.
Michael Harris, Chief Executive Officer of Biocomposites, said, “I’m delighted that our acquisition of Synimed has enriched our portfolio of products that support surgeon’s managing and treating infection. SYNICEM spacers already help many patients throughout the world and bringing them into the UK and wider Biocomposites network will ensure that more patients benefit.”
Biocomposites introduced SYNICEM hip, knee and shoulder preformed spacers in the United Kingdom.
SYNICEM spacers are antibiotic-loaded, preformed spacers designed to overcome the challenges of traditional intra-operative molded and handmade spacers. They help support revisions of the hip, knee and shoulder by preserving articular space and...
Biocomposites introduced SYNICEM hip, knee and shoulder preformed spacers in the United Kingdom.
SYNICEM spacers are antibiotic-loaded, preformed spacers designed to overcome the challenges of traditional intra-operative molded and handmade spacers. They help support revisions of the hip, knee and shoulder by preserving articular space and aiding the treatment of infection. Precision-engineered for consistency and structural uniformity, SYNICEM spacers provide a high local concentration of gentamicin and provide case-by-case flexibility to save surgeons time during their procedures.
The launch of SYNICEM spacers in the UK follows Biocomposites’ acquisition of French-based medical device manufacturer, Synimed, in 2022. Synimed specializes in bone cement and polymer-related products using in-house proprietary core polymer production and formulation.
Michael Harris, Chief Executive Officer of Biocomposites, said, “I’m delighted that our acquisition of Synimed has enriched our portfolio of products that support surgeon’s managing and treating infection. SYNICEM spacers already help many patients throughout the world and bringing them into the UK and wider Biocomposites network will ensure that more patients benefit.”
Copy to clipboard 
